Treatment resistant depression: Strategies for primary care topical collection on psychiatry in primary care

Current Psychiatry Reports

Volumn 15, Issue 7, 2013, Pages

  Preston, Taylor C ^a   Shelton, Richard C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antidepressant switch; Antidepressants; Augmentation; Combination therapy; Complementary and alternative therapy; Depression; Primary care; Psychiatry; Psychotherapy; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; LITHIUM SALT; METHYLFOLATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NATURAL PRODUCT; NORTRIPTYLINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; S ADENOSYLMETHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ARTICLE; COGNITIVE THERAPY; DEPRESSION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; PRIMARY MEDICAL CARE; PSYCHOTHERAPY; REMISSION; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; THERAPY RESISTANCE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; WEIGHT GAIN; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG COMBINATION; PROCEDURES;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84891715268     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0370-7     Document Type: Article

References (31)

1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR D report. Am J Psychiatry. 2006;163(11):1905-17.
2. • Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lanctot KL, Grysman NH. Sponsorship, antidepressant dose, and outcome in major depressive disorder: Meta-analysis of randomized controlled trials. J Clin Psychiatry. 2012;73(2):e277-87. This meta-analysis of antidepressant clinical trials identified a problem with inadequate dosing of comparator medications in industry-sponsored studies, using consensus dosing guidelines. The analysis found underdosing of the comparison medication in 37% of trials, while in only 5% was the sponsors medication underdosed.
3. Brook OH, van Hout HP, Stalman WA, de Haan M. Nontricyclic antidepressants: Predictors of nonadherence. J ClinPsychopharmacol. 2006;26(6):643-7.
4. •• Connolly KR, Thase ME. If at first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64. This is a comprehensive review of treatment alternatives in face of inadequate initial antidepressant response, including switching, augmentation, and antidepressant combinations.
5. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STARD) trial: A review. Can J Psychiatr Rev Can Psychiatr. 2010;55(3):126-35.
6. Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, et al. Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STARD. J Clin Psychopharmacol. 2012;32(1):114-9.
7. Hansen RA, Dusetzina SB, Ellis AR, Sturmer T, Farley JF, Gaynes BN. Risk of adverse events in treatment-resistant depression: Propensity-score-matched comparison of antidepressant augment and switch strategies. Gen Hosp Psychiatry. 2012;34(2):192-200.
8. Croft H, Settle Jr E, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21(4):643-58.
9. Gaynes BN, Farley JF, Dusetzina SB, Ellis AR, Hansen RA, Miller WC, et al. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? Depress Anxiety. 2011;28(11):989-98.
10. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J ClinPsychopharmacol. 2002;22(4):379-87.
11. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-96.
12. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: Implications for clinical practice. AmJPsychiatry. 2006;163(1):28-40.
13. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2):131-61.
14. Nelson JC, Maiure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry. 2004;55(3):296-300.
15. Nelson JC, Mazure CM, Bowers Jr MB, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48(4):303-7.
16. Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry. 2006;163(7):1219-25.
17. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183-8.
18. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion sr augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol. 2003;23(1):27-30.
19. Bauer M, Forsthoff A, Baethge C, Adli M, Berghofer A, Dopfmer S, et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci. 2003;253(3):132-9.
20. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996;16(4):307-14.
21. •• Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, et al. Lmethylfolate as adjunctive therapy for SSRIresistant major depression: results of two randomized, doubleblind, parallelsequential trials. Am J Psychiatry. 2012;169:1267-74. This paper reports was the first two doubleblind placebocontrolled clinical trials of lmethylfolate augmentation of SSRIs in treatment resistant patients. The first trial of 7.5 mg combination therapy did not separate from placebo. However, the second 15 mg augmentation was significantly better than placebo combination. These studies used a novel trial design called the sequential parallel comparison design (SPCD) which maximizes the ability to detect significant differences with relatively small sample sizes. For a more complete discussion of this method see Boessen R., Knol M., Groenwold R., Grobbee D., Roes K.: Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trials; Clin Trials 2012;9:578-587 and http://www.rctlogic.com/clinicaltrial/design.aspx.
22. •• Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: The american psychiatric association task force report. J ClinPsychiatry. 2010;71(6):669-81. This is an excellent, comprehensive review of complementary and alternative medicine options for depression. The paper reviews omega-3 fatty acids, s-adenosylmethionine (SAMe), st. John's Wort, folate, bright light therapy, acupuncture, exercise, mindfulness-based cognitive therapy, problem-solving therapy, and well-being therapy. This is an excellent teaching paper that reviews a wide range of non-pharmaceutical approaches for depression.
23. Alpert JE, Papakostas G, Mischoulon D, Worthington III JJ, Petersen T, Mahal Y, et al. S-adenosyl-l-methionine (same) as an adjunct for resistant major depressive disorder: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J ClinPsychopharmacol. 2004;24(6):661-4.
24. • Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (same) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942-8. This is the one double-blind, placebo controlled study of SAMe (800 mg. twice per day) as an add-on therapy for depressed patients who experienced insufficient response to any of several SSRI's. The HAM-D response and remission rates were higher for SAMe-treated patients (36.1% and 25.8%, respectively) than placebo (17.6% versus 11.7%, respectively). The number needed to treat for response and remission was approximately one in six and one in seven, indicating a moderate effect.
25. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-25.
26. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-91.
27. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study. J ClinPsychiatry. 2007;68(7):1071-7.
28. • Gaynes BN, Lux LJ, Lloyd SW, Hansen RA, Gartlehner G, Keener P, Brode S, Evans TS, Jonas D, Crotty K, Viswanathan M, Lohr KN. Nonpharmacologic interventions for treatment-resistant depression in adults. Rockville MD 2011. This is the most comprehensive review of the evidence supporting a wide range of non-pharmacological approaches to depression, including electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation (VNS), psychotherapies, including cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT). It is available online: http://www.ncbi.nlm.nih.gov/books/NBK65315/pdf/TOC.pdf.
29. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult ClinPsychol. 2007;75(2):267-76.
30. Simon GE, Lin EH, Katon W, Saunders K, VonKorff M, Walker E, et al. Outcomes of "inadequate" antidepressant treatment. J Gen InternMed. 1995;10:663-70.
31. Simon GE, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen HospPsychiatry. 1993;15:399-408.